Business Context and Reporting Period
This Form 6-K filing by InflaRx N.V. covers the month of April 2021, specifically dated April 15, 2021. The registrant is a foreign private issuer based in Jena, Germany, reporting pursuant to Rule 13A-16 under the Securities Exchange Act of 1934.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure rather than a financial statement.
Material Changes
The primary material event reported is the completion of patient enrollment for the Phase IIa clinical study of the company's drug candidate, vilobelimab, in the treatment of Pyoderma Gangraenosum.
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of the study milestone. The filing incorporates a press release as Exhibit 99.1 for further details. No specific financial guidance, risk factors, or contingencies are detailed within the body of this specific Form 6-K text.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for details on the Phase IIa study design and next steps.
- Confirm the timeline for the expected readout of data from the Pyoderma Gangraenosum study.
- Review the company's most recent Form 20-F for updated financial position and cash runway, as this filing contains no financial data.